Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study

Sorrento Therapeutics, Inc. has announced positive results from a phase IIa study of Abivertinib for the treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) in China. Abivertinib is a novel Bruton's tyrosine kinase (BTK) inhibitor that targets BTK irreversibly. The study included 27 R/R MZL patients treated with Abivertinib, and the overall response rate (ORR) was 59.3%, with 3 pat..